The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The Methylmalonic Acidemia (MMA) Market During 2026–2030?

The methylmalonic acidemia (mma) market size has experienced substantial growth in recent years. It is anticipated to increase from $9.94 billion in 2025 to $10.52 billion by 2026, at a compound annual growth rate (CAGR) of 5.8%. This historical expansion can be attributed to several factors, including heightened awareness of rare diseases, an increase in newborn screening programs, expanded research into metabolic disorders, advancements in diagnostic technologies, and the early adoption of genetic testing.

The market for methylmalonic acidemia (mma) is projected to experience robust expansion over the coming years, set to reach $13.06 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.6%. Factors contributing to this anticipated growth include the rise of precision therapeutics, breakthroughs in gene and enzyme replacement therapies, increasing capital directed towards rare disease drug development, the expansion of telehealth for metabolic monitoring, and a heightened emphasis on individualized nutrition strategies. Key trends anticipated during the forecast period encompass the evolution of precision medicine-driven treatments, AI-supported diagnostic and monitoring tools, integrated cloud-based data systems for rare diseases, automated production processes for enzyme therapies, and advanced immersive training programs for metabolic conditions.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22057&type=smp

What Factors Are Contributing To The Growth Of The Methylmalonic Acidemia (MMA) Market?

The methylmalonic acidemia (MMA) market is anticipated to grow with the rising prevalence of metabolic disorders and vitamin deficiencies. Metabolic disorders are conditions where the body struggles to process nutrients, generate energy, or regulate cellular reactions, while vitamin deficiencies occur when the body lacks adequate specific vitamins for proper function. The increase in these conditions is attributed to unhealthy diets, inactive lifestyles, and elevated stress levels, with modern eating habits often high in processed items and low in vital nutrients. These disorders, particularly vitamin B12 deficiency, disrupt methylmalonyl-CoA metabolism, causing methylmalonic acid to accumulate and worsen methylmalonic acidemia (MMA). For example, the National Institutes of Health, a US-based government agency, noted in November 2024 that vitamin B12 deficiency prevalence increased from 4.6% to 5.2%, equating to an additional 507 cases between the third and fourth quarters of 2023. The methylmalonic acidemia market is set to expand, driven by the growing neonatal and pediatric population, which refers to newborns within their initial 28 days and children under 18 years old. This demographic’s rise is largely due to advancements in maternal and neonatal healthcare services, resulting in higher survival rates and reduced infant mortality in developed nations. A larger neonatal and pediatric population boosts the demand for early diagnosis and treatment of metabolic disorders through expanded newborn screening programs. For instance, in October 2025, the Australian Bureau of Statistics, an Australia-based government agency, reported that 292,318 births were registered in 2024, reflecting a 1.9% rise (an additional 5,320 births) compared to 2023, with 150,299 male and 142,019 female babies.

Which Segment Categories Are Included In The Methylmalonic Acidemia (MMA) Market Segment Analysis?

The methylmalonic acidemia (mma) market covered in this report is segmented –

1) By Treatment Type: Dietary Management And Supplementation, Enzyme Replacement Therapy, Gene Therapy, Transplantation

2) By Disorder Type: Isolated Methylmalonic Aciduria, Combined Methylmalonic Aciduria, Homocystinuria

3) By Patient Age Group: Infant, Pediatric, Adult

4) By Route of Administration: Oral, Intravenous

5) By End User: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegments:

1) By Dietary Management And Supplementation: Vitamin B12 Supplementation, L-Carnitine Supplementation, Low-Protein Medical Diets

2) By Enzyme Replacement Therapy: Recombinant Enzyme Therapies, Investigational Enzymes

3) By Gene Therapy: AAV-Based Gene Therapy, Other Viral Vector-Based Therapies

4) By Transplantation: Liver Transplantation, Combined Liver–Kidney Transplantation

What Trends Are Shaping The Future Of The Methylmalonic Acidemia (MMA) Market?

Leading companies operating within the methylmalonic acidemia (MMA) market are concentrating on developing innovative solutions, such as mRNA-based therapies, aiming to improve treatment outcomes by addressing the underlying genetic causes of MMA and enhancing enzyme function to lessen the accumulation of toxic metabolites in affected individuals. mRNA-based therapies are a form of treatment that employs messenger RNA to instruct cells to produce specific proteins capable of helping to prevent or treat various diseases, including genetic disorders or infections. For example, in June 2024, Moderna, Inc., a US-based pharmaceutical and biotechnology company, secured U.S. Food and Drug Administration (FDA) approval for the inclusion of mRNA-3705 in the START pilot program, signifying a notable stride in advancing treatments for rare diseases. mRNA-3705 represents an investigational therapy for methylmalonic acidemia (MMA) stemming from MUT deficiency, specifically designed to restore the missing enzyme utilizing mRNA technology. The therapy makes use of Moderna’s proprietary lipid nanoparticle (LNP) system, which is also applied in the mRNA-3927 program for propionic acidemia. The FDA has awarded mRNA-3705 orphan drugs, fast track, and rare pediatric disease designations, thereby facilitating its accelerated development and clinical progression.

Who Are The Active Companies Shaping The Methylmalonic Acidemia (MMA) Market?

Major companies operating in the methylmalonic acidemia (mma) market are Alexion Pharmaceuticals Inc., PTC Therapeutics Inc., Asklepios BioPharmaceutical Inc AskBio, Selecta Biosciences Inc, BridgeBio Pharma Inc., VectivBio Holding AG, Recordati Rare Diseases Inc., Agios Pharmaceuticals Inc., LogicBio Therapeutics Inc., Moderna Inc., Wockhardt Limited, Supriya Lifescience Ltd., HemoShear Therapeutics LLC, Deccan Nutraceuticals Pvt Ltd, Genespire, Bluebird Bio Inc, Takeda Pharmaceutical Company Limited, Sanofi, Orphan Technologies Ltd, Ultragenyx Pharmaceutical Inc, HemoShear Therapeutics LLC

Get The Full Methylmalonic Acidemia (MMA) Market Report:

https://www.thebusinessresearchcompany.com/report/methylmalonic-acidemia-mma-global-market-report

Which Region Dominates The Methylmalonic Acidemia (MMA) Market By Market Share?

North America was the largest region in the methylmalonic acidemia (MMA) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the methylmalonic acidemia (mma) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Methylmalonic Acidemia (MMA) Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/methylmalonic-acidemia-mma-global-market-report

Browse Through More Reports Similar to the Global Methylmalonic Acidemia (MMA) Market 2026, By The Business Research Company

Metoprolol Tartrate Market Report 2026

https://www.thebusinessresearchcompany.com/report/metoprolol-tartrate-global-market-report

Methicillin Resistant Staphylococcus Aureus Mrsa Drugs Market Report

https://www.thebusinessresearchcompany.com/report/methicillin-resistant-staphylococcus-aureus-mrsa-drugs-global-market-report

Drug Formulation Market Report

https://www.thebusinessresearchcompany.com/report/drug-formulation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.